In the context of metabolic diseases such as NAFLD and SMA, liver dysfunction, including impaired lipid metabolism, may disrupt this axis, leading to abnormal glucagon secretion (Richter et al., 2022; Deng et al., 2024). This evidence concerns the gene GCG and metabolic disease.